- Home
- SONM vs QUCY Comparison
SONM vs QUCY Comparison
Compare SONM & QUCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SONM | QUCY |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | United States | Germany |
| Employees | N/A | 13 |
| Industry | Telecommunications Equipment | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 5.9M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SONM | QUCY |
|---|---|---|
| Price | $4.82 | $3.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.0K | ★ 30.0M |
| Earning Date | 04-14-2026 | 06-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $58,298,000.00 | N/A |
| Revenue This Year | N/A | $74.34 |
| Revenue Next Year | N/A | $171.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.52 | $0.30 |
| 52 Week High | $12.30 | $3.97 |
Technical Indicators
Market Signals| Indicator | SONM | QUCY |
|---|---|---|
| Relative Strength Index (RSI) | 55.68 | 93.25 |
| Support Level | $4.75 | $0.39 |
| Resistance Level | $5.45 | N/A |
| Average True Range (ATR) | 0.53 | 0.46 |
| MACD | 0.00 | 0.30 |
| Stochastic Oscillator | 49.38 | 67.06 |
Price Performance
Historical ComparisonAbout SONM Sonim Technologies Inc.
DNA X Inc is engaged in providing crypto trading services through its online platform, enabling users to buy, sell, and exchange cryptocurrencies, as well as execute automated trading strategies between currency pairs. The company generates revenue from commissions and fees on trading activity.
About QUCY Mainz Biomed N.V. Ordinary Shares
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.